Table 3. Clinical outcomes in exon 21 L861Q treated with TKI.
| Article reference | Research type | N, cases in the study | TKI therapy | ORR (%) | Median PFS (month) | Median OS (month) |
|---|---|---|---|---|---|---|
| Yang, 2015 (2) | Prospective | N=16 | 16 | 56.30% | 8.2 (4.5–16.6) | 17.1 (15.3–21.6) |
| L861Q [12] | 2nd | |||||
| L861Q + Others [4] | ||||||
| Zhang, 2017 (14) | Retrospective | N=5 | 5 | 0.00% | 5.7 (1.6–9.8) | NR |
| L861Q [4] | 1st | |||||
| L861Q + Others [1] | ||||||
| Wu, 2011 (24) | Retrospective | N=15 | 15 | 60.00% | 6.0 | 15.2 |
| L861Q/L861Q + Others [15] | 1st | |||||
| Xu, 2016 (16) | Retrospective | N=15 | 15 | 46.70% | 8.9 (4.47–13.34) | 21.98 (12.35–31.61) |
| L861Q [15] | 1st | |||||
| Chiu, 2015 (25) | Retrospective | N=66 | 66 | NR | ||
| L861Q [57] | 1st | 39.60% | 8.1 | |||
| L861Q + G719X [9] | 88.90% | 11.9 |
NR, not reported; TKI, tyrosine kinase inhibitor; ORR, objective response rate; PFS, progression-free survival.